In Brief: Unigene
Executive Summary
Unigene: Signs letter of intent with Warner-Lambert for worldwide rights to oral calcitonin for treatment of osteoporosis. Under the agreement, Warner-Lambert will assume responsibility for development and marketing of the product and Unigene will provide bulk active raw material. If the product development is successful, Warner-Lambert will make up-front and milestone payments of $50 mil., pay royalties, and purchase Unigene stock. The companies plan to execute a definitive agreement in mid-July...